GT Biopharma vs TuHURA Biosciences
GTBP and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GTBP and HURA compare
GT Biopharma is the larger company, worth 1.8 times as much as TuHURA Biosciences ($155M against $87.3M).
GT Biopharma scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GTBP | HURA |
|---|---|---|
| Size and price | ||
| Market cap | $155M | $87.3M |
| Share price | $3.43 | $1.37 |
| Change, 1 year | −80.0% | −27.1% |
| Change, 5 years | −99.9% | −99.9% |
| Beta (5Y) | 0.82 | 1.03 |
| Employees | 1 | 22 |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 26.7× | 4.7× (better) |
| FCF yield | – | −34.3% |
| Profitability | ||
| Return on equity | −231% | −161% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 3.50 (better) | 0.18 |
| Altman Z-score | −90.79 | −3.30 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −23.1% |
| Shareholder yield | 0.00% (better) | −23.1% |
| Ownership | ||
| Held by institutions | – | 14.1% |
| Held by insiders | 1.9% | 4.9% |
| Short interest, % of float | 0.56% | 10.2% |
Go deeper
- GTBP stock overview
- GTBP income statement
- GTBP valuation and score
- HURA stock overview
- HURA income statement
- HURA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.